Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 12, 2026 · Filed Mar 16, 2026
Zimmer Biomet's SVP and CHRO sold $251K of Zimmer Biomet shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$250,849
Shares × reported transaction price
30 days after results of Feb 10, 2026, 47 days before results of Apr 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $92.59 on Mar 12, 2026, 8% above its 52-week low and 18% below its high, after an 8% rise over the previous 30 trading days
52-week range $85.71 (Jan 28, 2026) to $113.18 (Mar 31, 2025), 25% of the way up, from 251 adjusted closes. 30 trading days earlier: $85.71 on Jan 28, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -6.7% | -2.6% | -4.1% |
| 30 days | +2.4% | +4.6% | -2.2% |
| 90 days | -4.6% | +12.5% | -17.1% |
| 180 days | +4.3% | +13.4% | -9.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.
